株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の潰瘍性大腸炎 (UC) 市場:機会分析と産業予測

Ulcerative Colitis Market by Molecule Type (Biologics and Small Molecules), by Disease Type, by Route of Administration - Global Opportunity Analysis and Industry Forecast, 2017-2023

発行 Allied Market Research 商品コード 563282
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.47円で換算しております。
Back to Top
世界の潰瘍性大腸炎 (UC) 市場:機会分析と産業予測 Ulcerative Colitis Market by Molecule Type (Biologics and Small Molecules), by Disease Type, by Route of Administration - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日: 2017年09月01日 ページ情報: 英文 150 Pages
概要

当レポートでは、世界の潰瘍性大腸炎 (UC) 市場について調査分析し、市場概要、セグメント別の市場分析、地域別分析、企業プロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場定義・範囲
  • 主な調査結果
  • ファイブフォース分析
  • 臨床試験
  • 市場シェア分析
  • 市場力学

第4章 潰瘍性大腸炎 (UC) 市場:疾患タイプ別

  • 概要
  • 軽症の潰瘍性大腸炎
  • 中等症の潰瘍性大腸炎
  • 重症の潰瘍性大腸炎

第5章 潰瘍性大腸炎 (UC) 市場:分子タイプ別

  • 概要
  • 小分子
  • 生物製剤

第6章 潰瘍性大腸炎 (UC) 市場:投与経路別

  • 概要
  • 経口
  • 注射

第7章 潰瘍性大腸炎 (UC) 市場:地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ

第8章 企業プロファイル

  • PFIZER INC.
  • JOHNSON & JOHNSON
  • GLAXOSMITHKLINE PLC
  • ELI LILLY AND CO.
  • SANOFI AVENTIS A/S
  • ASTRAZENECA PLC
  • MERCK & CO. INC.
  • ABBOTT LABORATORIES
  • INDEX PHARMACEUTICALS HOLDING AB
  • EAファーマ
目次
Product Code: LI 173965

Ulcerative colitis (UC) is an inflammatory gastrointestinal disease that affects colon or large intestine. UC is characterized as an incurable disease with low mortality rate and is generally diagnosed in adolescence and early adulthood. As per NCBI, about 1.86 billion patients were diagnosed with UC globally in 2014, with 1.54 billion patients currently receiving treatment. Moreover, it is estimated that in 2015, there were 2.1 million diagnosed cases of UC in U.S., Japan, and five major European countries namely Germany, France, Italy, Spain, and UK. The global ulcerative colitis market accounted for $4,785 million in 2016 and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023.

The major factors that drive the growth of the global ulcerative colitis market are increasing number of ulcerative colitis patients, new drug formulations by key players, and increasing investments by government and non-government organizations towards research in biologics. However, patent expiry and availability of alternative surgery option for UC treatment restricts the market growth. Conversely, untapped economies are expected to provide lucrative growth opportunities to the market.

The report segments the global ulcerative colitis market based on disease type, molecule type, and route of administration. Based on molecule type, the market is categorized as biologics and small molecules. In terms of disease type, the market is divided into mild, moderate, and severe ulcerative colitis. Based on route of administration, the market is bifurcated into oral and injectables. Regionally, the market is analyzed in North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS::

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global ulcerative colitis market.
  • Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities across the geographies.
  • This report entails the detailed quantitative analysis of the current market and estimations from 2016 to 2023 to identify the prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
  • Region- and country-wise ulcerative colitis market conditions are comprehensively analyzed in the report.

KEY MARKET SEGMENTS:

By Disease Type

  • Mild Ulcerative Colitis
  • Moderate Ulcerative Colitis
  • Severe Ulcerative Colitis

By Molecule Type

  • Biologics
  • Small Molecules

By Route of Administration

  • Oral
  • Injectables

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • South Korea
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Saudi Arabia
  • South Africa
  • Israel
  • Rest of LAMEA

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2 KEY BENEFITS
    • 1.1.1. Secondary research
    • 1.1.2. Primary research
    • 1.1.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. PORTERS FIVE FORCES ANALYSIS
  • 3.4. CLINICAL TRIALS
  • 3.5. MARKET SHARE ANALYSIS, 2016
  • 3.6. MARKET DYNAMICS
    • 3.6.1. Drivers
      • 3.6.1.1. Growing prevalence of ulcerative colitis disease
      • 3.6.1.2. Increase in R&D and investment by key players towards development of novel drug therapies
      • 3.6.1.3. Rise in government and non-government organization focus towards research in biologics
    • 3.6.2. Restraints
      • 3.6.2.1. Patent expiry of drugs
      • 3.6.2.2. Stringent government regulations towards approval of biosimilars
    • 3.6.3. Opportunities
      • 3.6.3.1. Untapped emerging economies

CHAPTER 4 ULCERATIVE COLITIS, BY DISEASE TYPE

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. MILD ULCERATIVE COLITIS
    • 4.2.1. Key market trends
    • 4.2.2. Growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. MODERATE ULCERATIVE COLITIS
    • 4.3.1. Key market trends
    • 4.3.2. Growth factors and opportunities
    • 4.3.3. Market size and forecast
  • 4.4. SEVERE ULCERATIVE COLITIS
    • 4.4.1. Key market trends
    • 4.4.2. Growth factors and opportunities
    • 4.4.3. Market size and forecast

CHAPTER 5 ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE

  • 5.1. OVERVIEW
    • 5.1.1. Market size and forecast
  • 5.2. SMALL MOLECULES
    • 5.2.1. Market size and forecast
  • 5.3. BIOLOGICS
    • 5.3.1. Market size and forecast

CHAPTER 6 ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1. OVERVIEW
    • 6.1.1. Market size and forecast
  • 6.2. ORAL
    • 6.2.1. Market size and forecast
  • 6.3. INJECTABLES
    • 6.3.1. Market size and forecast

CHAPTER 7 ULCERATIVE COLITIS MARKET, BY GEOGRAPHY

  • 7.1. OVERVIEW
    • 7.1.1. Market size and forecast
  • 7.2. NORTH AMERICA
    • 7.2.1. Key market trends
    • 7.2.2. Key growth factors and opportunities
    • 7.2.3. North America Market Size and Forecast for Ulcerative Colitis Market by Country
    • 7.2.4. North America Market Size and Forecast for Ulcerative Colitis Market by Disease Type
    • 7.2.5. North America Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
    • 7.2.6. North America Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.2.6.1. U.S. Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.2.6.2. U.S. Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.2.6.3. U.S. Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.2.6.4. Canada Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.2.6.5. Canada Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.2.6.6. Canada Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.2.6.7. Mexico Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.2.6.8. Mexico Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.2.6.9. Mexico Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
  • 7.3. EUROPE
    • 7.3.1. Key market trends
    • 7.3.2. Key growth factors and opportunities
    • 7.3.3. Europe Market Size and Forecast for Ulcerative Colitis Market by Country
    • 7.3.4. Europe Market Size and Forecast for Ulcerative Colitis Market by Disease Type
    • 7.3.5. Europe Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
    • 7.3.6. Europe Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.3.6.1. Germany Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.3.6.2. Germany Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.3.6.3. Germany Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.3.6.4. UK Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.3.6.5. UK Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.3.6.6. UK Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.3.6.7. Italy Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.3.6.8. Italy Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.3.6.9. Italy Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.3.6.10. France Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.3.6.11. France Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.3.6.12. France Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.3.6.13. Spain Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.3.6.14. Spain Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.3.6.15. Spain Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.3.6.16. Rest of Europe Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.3.6.17. Rest of Europe Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.3.6.18. Rest of Europe Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
  • 7.4. ASIA-PACIFIC
    • 7.4.1. Key market trends
    • 7.4.2. Key growth factors and opportunities
    • 7.4.3. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Country
    • 7.4.4. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Disease Type
    • 7.4.5. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
    • 7.4.6. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.4.6.1. Japan Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.4.6.2. Japan Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.4.6.3. Japan Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.4.6.4. China Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.4.6.5. China Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.4.6.6. China Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.4.6.7. India Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.4.6.8. India Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.4.6.9. India Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.4.6.10. Australia Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.4.6.11. Australia Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.4.6.12. Australia Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.4.6.13. South Korea Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.4.6.14. South Korea Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.4.6.15. South Korea Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.4.6.16. Rest of Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.4.6.17. Rest of Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.4.6.18. Rest of Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
  • 7.5. LAMEA
    • 7.5.1. Key market trends
    • 7.5.2. Key growth factors and opportunities
    • 7.5.3. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Country
    • 7.5.4. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Disease Type
    • 7.5.5. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
    • 7.5.6. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.5.6.1. South Africa Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.5.6.2. South Africa Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.5.6.3. South Africa Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.5.6.4. Saudi Arabia Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.5.6.5. Saudi Arabia Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.5.6.6. Saudi Arabia Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.5.6.7. Israel Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.5.6.8. Israel Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.5.6.9. Israel Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.5.6.10. Rest of LAMEA Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.5.6.11. Rest of LAMEA Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.5.6.12. Rest of LAMEA Market Size and Forecast for Ulcerative Colitis Market by Route of Administration

CHAPTER 8 COMPANY PROFILES

  • 8.1. PFIZER INC.
    • 8.1.1. Company overview
    • 8.1.2. Company snapshot
    • 8.1.3. Operating business segments
    • 8.1.4. Business performance
    • 8.1.5. Key strategic moves and developments
  • 8.2. JOHNSON & JOHNSON
    • 8.2.1. Company overview
    • 8.2.2. Company snapshot
    • 8.2.3. Operating business segments
    • 8.2.4. Business performance
    • 8.2.5. Key strategic moves and developments
  • 8.3. GLAXOSMITHKLINE PLC
    • 8.3.1. Company overview
    • 8.3.2. Company snapshot
    • 8.3.3. Operating business segments
    • 8.3.4. Business performance
    • 8.3.5. Key strategic moves and developments
  • 8.4. ELI LILLY AND CO.
    • 8.4.1. Company overview
    • 8.4.2. Company snapshot
    • 8.4.3. Operating business segments
    • 8.4.4. Business performance
    • 8.4.5. Key strategic moves and developments
  • 8.5. SANOFI AVENTIS A/S
    • 8.5.1. Company overview
    • 8.5.2. Company snapshot
    • 8.5.3. Operating business segments
    • 8.5.4. Business performance
    • 8.5.5. Key strategic moves and developments
  • 8.6. ASTRAZENECA PLC
    • 8.6.1. Company overview
    • 8.6.2. Company snapshot
    • 8.6.3. Operating business segments
    • 8.6.4. Business performance
    • 8.6.5. Key strategic moves and developments
  • 8.7. MERCK & CO. INC.
    • 8.7.1. Company overview
    • 8.7.2. Company snapshot
    • 8.7.3. Operating business segments
    • 8.7.4. Business performance
    • 8.7.5. Key strategic moves and developments
  • 8.8. ABBOTT LABORATORIES
    • 8.8.1. Company overview
    • 8.8.2. Company snapshot
    • 8.8.3. Operating business segments
    • 8.8.4. Business performance
    • 8.8.5. Key strategic moves and developments
  • 8.9. INDEX PHARMACEUTICALS HOLDING AB
    • 8.9.1. Company overview
    • 8.9.2. Company snapshot
    • 8.9.3. Operating business segments
    • 8.9.4. Key strategic moves and developments
  • 8.10. AJINOMOTO PHARMACEUTICALS CO., LTD.
    • 8.10.1. Company overview
    • 8.10.2. Company snapshot
    • 8.10.3. Operating business segments
    • 8.10.4. Key strategic moves and developments
Back to Top